Fig. 1

Bromocriptine treatment had an anti-leukemia activity in AML cell lines. a HL-60, KG-1, MonoMac-1 and Kasumi-1 AML cell lines were treated with 0.1, 1 and 10 µM bromocriptine for 48 h. Relative number of live cells refer to vehicle control-treated samples is represented. b HL-60 cells were treated with vehicle or 10 µM bromocriptine for 48 h. Frequency of Annexin-V-positive cells measured by flow cytometry is represented. c HL-60 cells were treated with bromocriptine at the concentrations indicated. Frequency of CD11b-positive cells detected by flow cytometry is represented. d HL-60 cells were treated with bromocriptine at 10 µM for 48 h. A representative picture of May–Grünwald–Giemsa-stained cells is shown. e HL-60 cells were cultured with HS-5 stroma cells at indicated concentration. Cell viability was measured 48 h after treatment by flow cytometry. Bars represent mean values of at least 3 experiments performed in triplicates. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001